Experienced leaders will spearhead operations and client services at the new U.S. headquarters and laboratory

经验丰富的领导者将率领新美国总部和实验室的运营及客户服务工作。

MARTINSRIED-MUNICH, Germany, October 07, 2025 / Biotech Newswire / --

马丁斯里德-慕尼黑，德国，2025年10月7日 /生物技术新闻社/ --

Coriolis Pharma

科里奥利制药

today announced the next step in its U.S. expansion by strengthening its team in North Carolina with the appointment of John Gabrielson as President of Coriolis Pharma US Inc. and Amber Raines as Senior Director, Client Project Management.

今天宣布了其在美国扩张的下一步，通过加强其在北卡罗来纳州的团队，任命约翰·加布里埃尔森为Coriolis制药美国公司总裁，安伯·雷恩斯为高级总监，客户项目管理。

In his role as President of Coriolis Pharma US Inc., John will lead the establishment of the new U.S. Headquarters and Laboratory, working closely with a highly skilled team to scale operations and build a strong foundation for future growth. He will play a pivotal role in executing Coriolis Pharma’s strategic vision and ensuring the successful rollout of service offerings tailored to the specific needs of the U.S.

约翰在担任Coriolis Pharma美国公司总裁期间，将领导建立新的美国总部和实验室，与一支高技能团队密切合作以扩大运营规模，并为未来的增长奠定坚实基础。他将在执行Coriolis Pharma的战略愿景中发挥关键作用，确保针对美国市场特定需求的服务顺利推出。

market. John brings over 20 years of experience in biologics development, having held senior leadership roles at both biotech companies and CDMOs. His expertise spans CMC planning, analytical sciences, and organizational strategy. John’s impressive track record includes founding Elion Labs and Similis Bio, leading large scientific teams in companies like KBI Biopharma and Amgen and contributing to the development and approval of more than 100 novel and biosimilar therapeutics..

市场。约翰在生物制品开发方面拥有超过20年的经验，曾担任生物技术公司和合同开发与生产组织（CDMO）的高级领导职务。他的专业知识涵盖化学、制造和控制（CMC）规划、分析科学以及组织战略。约翰的卓越履历包括创立了Elion Labs和Similis Bio，领导KBI生物制药和安进等公司的大型科学团队，并参与了100多种创新和生物类似治疗药物的开发与批准工作。

Amber Raines joins the U.S. commercial team as Senior Director, Client Project Management, where she will lead the client project management group. With her deep scientific expertise and strong background in pharmaceutical development, Amber will ensure the successful execution of client projects and serve as a key interface between clients and internal teams.

琥珀·雷恩斯加入美国商业团队，担任高级总监，客户项目管理，她将领导客户项目管理小组。凭借其深厚的科学专业知识和在药物开发方面的强大背景，琥珀将确保客户项目的成功执行，并作为客户与内部团队之间的关键接口。

Amber brings extensive experience in pharmaceutical development and project leadership. She previously served as Senior Director Rapid Analytics at KBI Biopharma in Louisville, Colorado, and held roles including Director of the Particle Characterization Core Facility at KBI Biopharma. Before, she held various positions at KBI Biopharma, Amgen, and Merck & Co., among others..

Amber在制药开发和项目领导方面拥有丰富的经验。她此前曾担任科罗拉多州路易斯维尔KBI生物制药公司的高级总监快速分析部门，并担任过KBI生物制药公司颗粒表征核心设施总监等职务。在此之前，她曾在KBI生物制药、安进和默克公司等企业担任过多个职位。

“With John and Amber, we are gaining two outstanding professionals who share our vision and will play a key role in strengthening our presence in the U.S. market,”

“约翰和安伯的加入为我们带来了两位杰出的专业人士，他们与我们有着共同的愿景，并将在加强我们在美国市场的地位方面发挥关键作用。”

says Silvia Steyrer-Gruber, CEO of Coriolis Pharma.

Coriolis Pharma首席执行官西尔维娅·施泰尔-格鲁伯说。

“Their leadership and deep expertise make them a perfect fit for Coriolis. As we expand our footprint in the U.S. their contributions will be instrumental in launching our operational activities at the new laboratory and headquarters, and enabling us to offer our on-site services to our clients early next year.”.

“他们的领导能力和深厚的专业知识使他们非常适合Coriolis。随着我们扩大在美国的业务，他们的贡献将在新实验室和总部启动运营活动时发挥关键作用，并使我们能够明年年初向客户提供现场服务。”

For high resolution please click the images.

请单击图像以获取高分辨率。

About

关于

Coriolis Pharma

科里奥利制药

Coriolis Pharma is a globally operating contract research and development organization (CRDO) and the premier partner for drug product development, analytical services and manufacturing services across a vast array of biological therapeutic modalities. With a focus on liquid and lyophilized drug products, Coriolis expert scientists design and execute platform and custom services to accelerate and derisk client programs right from the start and throughout the entire product lifecycle..

科里奥利制药是一家全球运营的合同研究与开发组织（CRDO），也是各类生物治疗模式中药品开发、分析服务和生产服务的首选合作伙伴。专注于液体制剂和冻干制剂，科里奥利的专家科学家们设计并执行平台化和定制化服务，从项目初始到整个产品生命周期，助力客户加速进程并降低风险。

Headquartered in Martinsried near Munich, the company offers tailored solutions from early development stages to market approval. Coriolis Pharma stands out for its scientific excellence, innovative analytical methods, and deep understanding of formulation and drug product development.

总部位于慕尼黑附近的马丁斯里德，该公司提供从早期开发阶段到市场批准的定制解决方案。Coriolis Pharma 以其科学卓越、创新的分析方法以及对配方和药物产品开发的深刻理解而脱颖而出。

With the establishment of its new laboratory and U.S. headquarters in North Carolina, Coriolis Pharma is expanding its global footprint and bringing its high-quality services closer to clients in the United States.

随着其新实验室和美国总部在北卡罗来纳州的建立，科里奥利斯制药公司正在扩大其全球足迹，并将高质量的服务带给美国的客户。

Contact

联系

Coriolis Pharma

科里奥利制药

Bettina von Klitzing-Stückle

贝蒂娜·冯·克利青-施图克勒

Marketing Manager

营销经理

+49 (0) 89 4177 60 – 0

+49 (0) 89 4177 60 – 0

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Leadership; Appointments and Schedules; Drug Delivery Systems; Drug Development; Drug Compounding; Laboratories; Biological Products; Pharmaceutical Preparations; Biotechnology; Coriolis Pharma; U.S. expansion; North Carolina; John Gabrielson; Coriolis Pharma US Inc.; Amber Raines; biologics development; CDMOs; Silvia Steyrer-Gruber; contract research and development organization (CRDO); drug product development; analytical services; manufacturing services; biological therapeutic modalities; liquid drug products; lyophilized drug products; formulation development.

关键词：领导力；任命与日程；药物递送系统；药物开发；药物配制；实验室；生物制品；医药制剂；生物技术；Coriolis Pharma；美国扩展；北卡罗来纳州；John Gabrielson；Coriolis Pharma美国公司；Amber Raines；生物制品开发；合同开发和生产组织（CDMO）；Silvia Steyrer-Gruber；合同研究与开发组织（CRDO）；药物产品开发；分析服务；制造服务；生物治疗模式；液体制剂；冻干制剂；配方开发。

Source: Biotech Newswire

来源：生物技术通讯社